Curosurf
Company: Dey Laboratories
Approval Status: Approved October 1998
Treatment for: Pediatric Respiratory Distress Syndrome
Areas: Pediatrics/Neonatology; Pulmonary/Respiratory Diseases
General Information
Other Useful Resources
Curosurf is used as a treatment for respiratory distress syndrome in premature infants.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
